OCEAN, said Albert, provides important risk-benefit data that doctors can now use in discussions with their patients. For ...
NEW ORLEANS, LA—Among patients with atrial fibrillation (AF) undergoing PCI, 1 month of dual therapy with a direct oral ...
The drug, given as a weekly subcutaneous injection, reduced both triglycerides and liver fat in the phase II trial.
The approach is “very exciting,” but one expert says a lot more research is needed, especially around safety, before clinical ...
It’s the first study to show a PCSK9 inhibitor can reduce major events in high-risk patients who haven’t yet had one.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback